NO331030B1 - Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase - Google Patents

Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase

Info

Publication number
NO331030B1
NO331030B1 NO20045267A NO20045267A NO331030B1 NO 331030 B1 NO331030 B1 NO 331030B1 NO 20045267 A NO20045267 A NO 20045267A NO 20045267 A NO20045267 A NO 20045267A NO 331030 B1 NO331030 B1 NO 331030B1
Authority
NO
Norway
Prior art keywords
reverse transcriptase
inhibitory activity
activity against
nucleoside reverse
pyrimidine compounds
Prior art date
Application number
NO20045267A
Other languages
English (en)
Norwegian (no)
Other versions
NO20045267L (no
Inventor
Marie-Pierre T M M G De Bethune
Paul Stoffels
Jens Marcel Van Roey
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20045267L publication Critical patent/NO20045267L/no
Publication of NO331030B1 publication Critical patent/NO331030B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pyridine Compounds (AREA)
NO20045267A 2002-05-13 2004-12-01 Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase NO331030B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076897 2002-05-13
PCT/EP2003/050158 WO2003094920A1 (en) 2002-05-13 2003-05-13 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission

Publications (2)

Publication Number Publication Date
NO20045267L NO20045267L (no) 2005-02-14
NO331030B1 true NO331030B1 (no) 2011-09-19

Family

ID=29414777

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20045267A NO331030B1 (no) 2002-05-13 2004-12-01 Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase
NO20110298A NO334067B1 (no) 2002-05-13 2011-02-22 Anvendelse av triazinforbindelser for fremstilling av legemidler til forebygging av seksuell overføring av HIV

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20110298A NO334067B1 (no) 2002-05-13 2011-02-22 Anvendelse av triazinforbindelser for fremstilling av legemidler til forebygging av seksuell overføring av HIV

Country Status (26)

Country Link
US (4) US7935710B2 (pl)
EP (1) EP1505980B1 (pl)
JP (2) JP4530848B2 (pl)
KR (1) KR101095358B1 (pl)
CN (2) CN1668305B (pl)
AP (1) AP2024A (pl)
AR (1) AR039540A1 (pl)
AT (1) ATE376420T1 (pl)
AU (1) AU2003240844B2 (pl)
BR (2) BRPI0310021B8 (pl)
CA (1) CA2486078C (pl)
CY (1) CY1110249T1 (pl)
DE (1) DE60317060T2 (pl)
DK (1) DK1505980T3 (pl)
EA (1) EA011298B1 (pl)
ES (1) ES2294291T3 (pl)
HR (1) HRP20041177B1 (pl)
IL (1) IL165174A (pl)
MX (1) MXPA04011392A (pl)
NO (2) NO331030B1 (pl)
NZ (1) NZ536976A (pl)
PL (1) PL215128B1 (pl)
PT (1) PT1505980E (pl)
SI (1) SI1505980T1 (pl)
WO (1) WO2003094920A1 (pl)
ZA (1) ZA200409984B (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
ITMI20031640A1 (it) 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
ES2533258T3 (es) * 2005-02-18 2015-04-08 Janssen Sciences Ireland Uc Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH
RU2409368C2 (ru) * 2005-04-27 2011-01-20 Шэньчжэнь Флора Байотекнолоджи Лимитед Композиция и способ регуляции и поддержания бактериальной микрофлоры и кислотности влагалища
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007071199A1 (en) * 2005-12-22 2007-06-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences 2,4-disubstituted amido-6-substituted-[1,3,5]triazine or 1,3-pyrimidine compounds, their processes for preparation, their pharmaceutical compositions and uses thereof
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2008152195A (ru) 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
WO2007146977A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
CN101553483B (zh) * 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
JP5185283B2 (ja) * 2006-12-29 2013-04-17 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害６−置換ピリミジン
EP2114902B1 (en) * 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv inhibiting 5,6-substituted pyrimidines
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CN105367503A (zh) 2007-10-19 2016-03-02 阿维拉制药公司 杂芳基化合物和其用途
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
HRP20172006T1 (hr) 2010-11-10 2018-02-09 Genentech, Inc. Derivati pirazol-aminopiridina kao lrrk2-modulatori
US20130039959A1 (en) * 2011-04-19 2013-02-14 Brian Vincent Sokol Method of inhibiting hiv and barrier-forming composition therefor
CA3079323A1 (en) 2011-04-19 2012-10-26 Arms Pharmaceutical Llc. Method of inhibiting harmful microorganisms and barrier-forming composition therefor
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
CN102675212B (zh) * 2012-05-09 2014-11-05 昆明理工大学 N-取代苯基-2-((1h-苯并咪唑-2-基)巯基)乙酰胺类衍生物及其用途
JP2016501203A (ja) 2012-11-20 2016-01-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
JP6466107B2 (ja) * 2014-09-04 2019-02-06 東ソー・ファインケム株式会社 ４−フェニルチオ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105085410B (zh) * 2015-08-21 2017-10-10 武汉工程大学 一种二芳基嘧啶类hiv‑1抑制剂及其制备方法
EP3370701A1 (en) 2015-11-06 2018-09-12 INEB-Instituto Nacional De Engenharia Biomédica A composition for use in a method for prevention or treatment of human immunodeficiency virus infections
CN106478521A (zh) * 2016-10-11 2017-03-08 武汉工程大学 一种二芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法
CN106866628A (zh) * 2017-02-27 2017-06-20 武汉工程大学 一种芳基杂芳基嘧啶类hiv‑1逆转录酶抑制剂及其制备方法
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
CN109053613A (zh) * 2018-07-04 2018-12-21 复旦大学 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途
CA3115351C (en) * 2018-12-04 2023-06-20 Virox Technologies Inc. An antimicrobial composition comprising an antimicrobial agent consisting of a c3-c5 n-alkyl-gamma-butyrolactam and uses thereof
US12053540B2 (en) 2018-12-04 2024-08-06 Virox Technologies Inc. Antimicrobial compositions containing solvents including a C3-C5 N-alkyl-gamma-butyrolactam
US12532886B2 (en) 2018-12-04 2026-01-27 Virox Technologies Inc. Method of killing microbes using C3-C5 n-alkyl-gamma-butyrolactams and antimicrobial compositions containing same
US12052990B2 (en) 2018-12-04 2024-08-06 Virox Technologies Inc. C3-C5 n-alkyl-gamma-butyrolactam containing antimicrobial compositions and methods of using same
US20220033851A1 (en) * 2020-08-03 2022-02-03 Roger B. Swartz mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20250302939A1 (en) 2022-05-10 2025-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Vaccine for human t-lymphotropic virus-1

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983393A (en) * 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
PL163814B1 (en) 1988-01-20 1994-05-31 Univ Minnesota Method of obtaining novel analogous compounds of dideoxy-didehydrocarbocyclic nucleosides
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JPH075465B2 (ja) 1990-03-29 1995-01-25 三菱化学株式会社 抗ウイルス剤
JP3094036B2 (ja) 1990-07-19 2000-10-03 ザ ウエルカム ファウンデーション リミテッド 酵素不活性化剤
GB9214720D0 (en) * 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
CA2168447C (en) * 1993-08-24 2006-07-11 Peter Thomas Lind Compounds and methods for inhibition of hiv and related viruses
US6165493A (en) * 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
CZ299380B6 (cs) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
HRP20080359B1 (hr) * 1998-11-10 2016-01-01 Janssen Pharmaceutica N.V. PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
AU764472B2 (en) * 1998-11-10 2003-08-21 Janssen Pharmaceutica N.V. 2,4-disubstituted triazine derivatives
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
MXPA01011606A (es) * 1999-05-14 2003-09-10 Univ California Terapia anti-inflamatoria para infeccion mediada por inflamacion.
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CA2384188C (en) * 1999-09-24 2008-06-17 Janssen Pharmaceutica N.V. Antiviral compositions
AU769292B2 (en) 2000-05-05 2004-01-22 F. Hoffmann-La Roche Ag Sentinel virus II
JP4969010B2 (ja) 2000-05-08 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害性ピリミジンのプロドラッグ
WO2001085700A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
JP2004525914A (ja) 2001-03-02 2004-08-26 スミスクライン ビーチャム コーポレーション 逆転写酵素阻害剤としてのベンゾフェノン類
US6951654B2 (en) 2001-03-27 2005-10-04 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina

Also Published As

Publication number Publication date
CN1668305A (zh) 2005-09-14
IL165174A (en) 2011-01-31
EA011298B1 (ru) 2009-02-27
NO20110298L (no) 2005-02-14
US20200345733A1 (en) 2020-11-05
AP2004003182A0 (en) 2004-12-31
HRP20041177A2 (hr) 2006-04-30
AU2003240844B2 (en) 2008-09-11
US20060166943A1 (en) 2006-07-27
HRP20041177B1 (hr) 2013-03-31
NO334067B1 (no) 2013-12-02
WO2003094920A1 (en) 2003-11-20
IL165174A0 (en) 2005-12-18
BR0310021A (pt) 2005-02-15
EP1505980B1 (en) 2007-10-24
ATE376420T1 (de) 2007-11-15
MXPA04011392A (es) 2005-02-17
NZ536976A (en) 2007-08-31
AU2003240844A1 (en) 2003-11-11
BRPI0310021B1 (pt) 2018-03-13
CN102558070A (zh) 2012-07-11
US20110165093A1 (en) 2011-07-07
CA2486078C (en) 2011-08-23
US20170100399A1 (en) 2017-04-13
BR122014006936B8 (pt) 2021-05-25
PT1505980E (pt) 2008-01-17
EA200401494A1 (ru) 2005-06-30
DK1505980T3 (da) 2008-02-11
CY1110249T1 (el) 2015-01-14
BRPI0310021B8 (pt) 2021-05-25
AP2024A (en) 2009-08-11
EP1505980A1 (en) 2005-02-16
NO20045267L (no) 2005-02-14
JP4530848B2 (ja) 2010-08-25
KR20050010798A (ko) 2005-01-28
ZA200409984B (en) 2006-07-26
JP2010189435A (ja) 2010-09-02
DE60317060T2 (de) 2008-07-24
PL215128B1 (pl) 2013-10-31
JP2005526846A (ja) 2005-09-08
JP5256244B2 (ja) 2013-08-07
ES2294291T3 (es) 2008-04-01
CN1668305B (zh) 2013-06-12
US7935710B2 (en) 2011-05-03
SI1505980T1 (sl) 2008-02-29
PL373840A1 (pl) 2005-09-19
KR101095358B1 (ko) 2011-12-16
CA2486078A1 (en) 2003-11-20
AR039540A1 (es) 2005-02-23
BR122014006936B1 (pt) 2020-11-24
DE60317060D1 (de) 2007-12-06
CN102558070B (zh) 2016-01-13
HK1173141A1 (zh) 2013-05-10

Similar Documents

Publication Publication Date Title
NO331030B1 (no) Pyrimidinforbindelser med inhibitorisk aktivitet overfor ikke-nukleosid revers transkriptase
BR0309557A (pt) Inibidores da transcriptase reversa não nucleosìdeos
CY1110690T1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
MX2009005009A (es) Compuestos heterociclicos biciclicos 4-cianofenilamino sustituidos como inhibidores del virus de inmunodeficiencia humana.
HN2004000146A (es) Dihidroquinazolinas sustituidas
NO20090322L (no) 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
NO20054143D0 (no) Pyrimidinderivater for forhindringen av HIV-infeksjon
NO20052787L (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
NO20054264D0 (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
DE60324014D1 (de) Heterocyclische verbindungen alsccr5-antagonisten
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
WO2006122003A3 (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
WO2003002064A3 (en) Fused pyrimidine dhfr inhibitors as antibacterials
DK1246808T3 (da) 1,2-diarylbenzimidazoler til behandling af sygdomme, som er associeret med en mikroglia-aktivering
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
SE0100733D0 (sv) Non-nucleoside reverse transcriptase inhibitors
GT200300229A (es) Utilizacion de pirimetanilo en patogenos resistentes
ECSP044980A (es) Composición herbicida
AU7076600A (en) Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
TH85131A (th) สารประกอบฆ่าจุลินทรีย์ซึ่งมีไพริมิดีนหรือไทรอะซีน

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: JANSSEN SCIENCES IRELAND UC, IE

MK1K Patent expired